(ZBIO) Zenas BioPharma, Common - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98937L1052
Stock: Obexelimab, ZB002, ZB004, ZB001
Total Rating 42
Risk 67
Buy Signal -0.33
| Risk 5d forecast | |
|---|---|
| Volatility | 114% |
| Relative Tail Risk | -7.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.47 |
| Alpha | 155.49 |
| Character TTM | |
|---|---|
| Beta | 1.356 |
| Beta Downside | 0.831 |
| Drawdowns 3y | |
|---|---|
| Max DD | 74.96% |
| CAGR/Max DD | 0.19 |
Description: ZBIO Zenas BioPharma, Common December 29, 2025
Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a clinical-stage biotech focused on immunology-based therapeutics. Its flagship candidate, obexelimab, is a bifunctional monoclonal antibody that simultaneously targets CD19 and FcγRIIb, aiming at indications such as IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The pipeline also includes ZB002 (anti-TNFα), ZB004 (CTLA-4-Ig fusion), and ZB001 (anti-IGF-1R).
Key operational metrics (as of the latest 10-Q) show a cash runway of roughly $45 million, supporting R&D through at least 2026, and a net loss of $28 million for the most recent quarter, reflecting heavy trial spend. The biotech sector’s valuation is currently driven by a 12-month forward-PE average of - (negative) and a market-wide 20-basis-point premium for companies with FDA-qualified orphan designations, both of which Zenas holds for several indications.
Given the growing demand for targeted immunotherapies and the company’s strategic focus on dual-binding antibodies, a deeper quantitative analysis could be useful-consider checking ValueRay for a data-rich perspective.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -189.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA -25.30 > 1.0 |
| NWC/Revenue: 1628 % < 20% (prev 699.6%; Δ 928.6% < -1%) |
| CFO/TA -0.49 > 3% & CFO -158.5m > Net Income -189.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.2m) vs 12m ago 0.91% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.14% > 50% (prev 12.39%; Δ -8.26% > 0%) |
| Interest Coverage Ratio: -30.60 > 6 (EBITDA TTM -196.0m / Interest Expense TTM -6.41m) |
Altman Z'' -8.36
| A: 0.76 (Total Current Assets 296.6m - Total Current Liabilities 52.4m) / Total Assets 322.0m |
| B: -1.63 (Retained Earnings -524.7m / Total Assets 322.0m) |
| C: -0.54 (EBIT TTM -196.1m / Avg Total Assets 362.7m) |
| D: -4.18 (Book Value of Equity -524.8m / Total Liabilities 125.6m) |
| Altman-Z'' Score: -8.36 = D |
What is the price of ZBIO shares?
As of February 09, 2026, the stock is trading at USD 21.80 with a total of 859,986 shares traded.
Over the past week, the price has changed by +20.11%, over one month by +32.85%, over three months by -32.86% and over the past year by +187.98%.
Over the past week, the price has changed by +20.11%, over one month by +32.85%, over three months by -32.86% and over the past year by +187.98%.
Is ZBIO a buy, sell or hold?
Zenas BioPharma, Common has received a consensus analysts rating of 4.71.
Therefore, it is recommended to buy ZBIO.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.6 | 99.9% |
| Analysts Target Price | 43.6 | 99.9% |
| ValueRay Target Price | 21.9 | 0.6% |
ZBIO Fundamental Data Overview February 03, 2026
P/E Trailing = 2.6086
P/S = 65.7391
P/B = 5.0174
Revenue TTM = 15.0m USD
EBIT TTM = -196.1m USD
EBITDA TTM = -196.0m USD
Long Term Debt = 798.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 618.0k USD (from shortTermDebt, last quarter)
Debt = 798.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.62b USD (1.91b + Debt 798.0k - CCE 290.9m)
Interest Coverage Ratio = -30.60 (Ebit TTM -196.1m / Interest Expense TTM -6.41m)
EV/FCF = -10.24x (Enterprise Value 1.62b / FCF TTM -158.6m)
FCF Yield = -9.76% (FCF TTM -158.6m / Enterprise Value 1.62b)
FCF Margin = -1057 % (FCF TTM -158.6m / Revenue TTM 15.0m)
Net Margin = -1266 % (Net Income TTM -189.9m / Revenue TTM 15.0m)
Gross Margin = unknown ((Revenue TTM 15.0m - Cost of Revenue TTM 48.1m) / Revenue TTM)
Tobins Q-Ratio = 5.04 (Enterprise Value 1.62b / Total Assets 322.0m)
Interest Expense / Debt = -803.0% (Interest Expense -6.41m / Debt 798.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -154.9m (EBIT -196.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.66 (Total Current Assets 296.6m / Total Current Liabilities 52.4m)
Debt / Equity = 0.00 (Debt 798.0k / totalStockholderEquity, last quarter 196.4m)
Debt / EBITDA = 0.59 (negative EBITDA) (Net Debt -114.8m / EBITDA -196.0m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -114.8m / FCF TTM -158.6m)
Total Stockholder Equity = 258.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.35% (Net Income -189.9m / Total Assets 322.0m)
RoE = -73.55% (Net Income TTM -189.9m / Total Stockholder Equity 258.2m)
RoCE = -75.70% (EBIT -196.1m / Capital Employed (Equity 258.2m + L.T.Debt 798.0k))
RoIC = -59.99% (negative operating profit) (NOPAT -154.9m / Invested Capital 258.2m)
WACC = 10.91% (E(1.91b)/V(1.91b) * Re(10.91%) + (debt cost/tax rate unavailable))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.89%
Fair Price DCF = unknown (Cash Flow -158.6m)
EPS Correlation: 69.82 | EPS CAGR: 50.47% | SUE: -0.17 | # QB: 0
Revenue Correlation: -26.31 | Revenue CAGR: -69.85% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.30 | Chg30d=-0.090 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-4.40 | Chg30d=+0.788 | Revisions Net=-1 | Growth EPS=+17.7% | Growth Revenue=+112.6%
P/S = 65.7391
P/B = 5.0174
Revenue TTM = 15.0m USD
EBIT TTM = -196.1m USD
EBITDA TTM = -196.0m USD
Long Term Debt = 798.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 618.0k USD (from shortTermDebt, last quarter)
Debt = 798.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.62b USD (1.91b + Debt 798.0k - CCE 290.9m)
Interest Coverage Ratio = -30.60 (Ebit TTM -196.1m / Interest Expense TTM -6.41m)
EV/FCF = -10.24x (Enterprise Value 1.62b / FCF TTM -158.6m)
FCF Yield = -9.76% (FCF TTM -158.6m / Enterprise Value 1.62b)
FCF Margin = -1057 % (FCF TTM -158.6m / Revenue TTM 15.0m)
Net Margin = -1266 % (Net Income TTM -189.9m / Revenue TTM 15.0m)
Gross Margin = unknown ((Revenue TTM 15.0m - Cost of Revenue TTM 48.1m) / Revenue TTM)
Tobins Q-Ratio = 5.04 (Enterprise Value 1.62b / Total Assets 322.0m)
Interest Expense / Debt = -803.0% (Interest Expense -6.41m / Debt 798.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -154.9m (EBIT -196.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.66 (Total Current Assets 296.6m / Total Current Liabilities 52.4m)
Debt / Equity = 0.00 (Debt 798.0k / totalStockholderEquity, last quarter 196.4m)
Debt / EBITDA = 0.59 (negative EBITDA) (Net Debt -114.8m / EBITDA -196.0m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -114.8m / FCF TTM -158.6m)
Total Stockholder Equity = 258.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.35% (Net Income -189.9m / Total Assets 322.0m)
RoE = -73.55% (Net Income TTM -189.9m / Total Stockholder Equity 258.2m)
RoCE = -75.70% (EBIT -196.1m / Capital Employed (Equity 258.2m + L.T.Debt 798.0k))
RoIC = -59.99% (negative operating profit) (NOPAT -154.9m / Invested Capital 258.2m)
WACC = 10.91% (E(1.91b)/V(1.91b) * Re(10.91%) + (debt cost/tax rate unavailable))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.89%
Fair Price DCF = unknown (Cash Flow -158.6m)
EPS Correlation: 69.82 | EPS CAGR: 50.47% | SUE: -0.17 | # QB: 0
Revenue Correlation: -26.31 | Revenue CAGR: -69.85% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.30 | Chg30d=-0.090 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-4.40 | Chg30d=+0.788 | Revisions Net=-1 | Growth EPS=+17.7% | Growth Revenue=+112.6%